Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OligoTreat: clemastine plus aerobic exercise for cognitive dysfunction in schizophrenia
2024-514457-30-00Phase 2Authorised
- Sponsor
- LMU Klinikum
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in schizophrenia and Schizophrenia Spectrum Disorders (SSD) comparing Clemastine plus aerobic exercise with Placebo plus aerobic exercise (2 arms). Primary endpoints: Change in working memory performance and Change in global functioning. Planned start Feb 2024; status: authorised.
02
Drugs
clemastine
03
Conditions
schizophreniaSchizophrenia Spectrum Disorders (SSD)
Beyond the preview
Go deeper on 2024-514457-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514457-30-00.